Citations

Showing 10 of 108104 citations.

Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre
Asioli, Sofia , Righi, Alberto , Iommi, Marica , Baldovini, Chiara , Ambrosi, Francesca , Guaraldi, Federica , Zoli, Matteo , Faustini‐Fustini, Marco, Rucci, Paola , Asioli, Sofia , Zoli, Matteo , Righi, Alberto , Mazzatenta, Diego , Giannini, Caterina , Foschini, Maria Pia

Mayo Clinic

European Journal of Endocrinology | November 27, 2018 | Volume: 180 | Issue: 2 | Pages: 127-134

10.1530/eje-18-0749 | PMID 30481158 Get It

Objective and design A clinicopathological score has been proposed by Trouillas et al. to predict the evolution of pituitary adenomas. Aim of our study was to perform an independent external validation of this score and identify other potential predictor of post-surgical outcome. Methods The study sample included 566 patients with pituitary adenomas, specifically 253 FSH/LH-secreting, 147 GH-secreting, 85 PRL-secreting, 72 ACTH-secreting and 9 TSH-secreting tumours with at least 3-year post-surgical follow-up. Results In 437 cases, pituitary adenomas were non-invasive, with low (grade 1a: 378 cases) or high (grade 1b: 59 cases) proliferative activity. In 129 cases, tumours were invasive, with low (grade 2a: 87 cases) or high (grade 2b: 42 cases) proliferative activity. During the follow-up (mean: 5.8 years), 60 patients developed disease recurrence or progression, with a total of 130 patients with pituitary disease at last follow-up. Univariate analysis demonstrated a significantly higher risk of disease persistence and recurrence/progression in patients with PRL-, ACTH- and FSH/LH-secreting tumours as compared to those with somatotroph tumours, and in those with high proliferative activity (grade 1b and 2b) or >1 cm diameter. Multivariate analysis confirmed tumour type and grade to be independent predictors of disease-free-survival. Tumour invasion, Ki-67 and tumour type were the only independent prognostic factors of disease-free survival. Conclusions Our data confirmed the validity of Trouillas’ score, being tumour type and grade independent predictors of disease evolution. Therefore, we recommend to always consider both features, together with tumour histological subtype, in the clinical setting to early identify patients at higher risk of recurrence.
Health Care Costs and Cost‐effectiveness in Laryngotracheal Stenosis
Yin, Linda X. , Padula, William V. , Gadkaree, Shekhar K. , Motz, Kevin , Rahman, Sabrina , Gelbard, Alexander , Motz, Kevin M , Yin, Linda X , Gelbard, Alexander , Predmore, Zachary , Hillel, Alexander T.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | November 27, 2018 | Volume: 160 | Issue: 4 | Pages: 679-686

10.1177/0194599818815068 | PMID 30481123 Get It

ObjectiveLaryngotracheal stenosis (LTS) is resource‐intensive disease. The cost‐effectiveness of LTS treatments has not been adequately explored. We aimed to conduct a cost‐effectiveness analysis comparing open reconstruction (cricotracheal/tracheal resection [CTR/TR]) with endoscopic dilation in the treatment of LTS.Study DesignRetrospective cohort.SettingTertiary referral center (2013‐2017).Subjects and MethodsThirty‐four LTS patients were recruited. Annual costs were derived from the Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins University. Cost‐effectiveness analysis compared CTR/TR versus endoscopic dilation at a willingness‐to‐pay threshold of $50,000 per quality‐adjusted life year (QALY) over 5‐ and 10‐year time horizons. The incremental cost‐effectiveness ratio (ICER) was calculated with deterministic analysis and tested for sensitivity with univariate and probabilistic sensitivity analysis.ResultsMean LTS costs were $4080.09 (SE, $569.29) annually for related health care visits. The major risk factor for increased cost was etiology of stenosis. As compared with idiopathic patients, patients with intubation‐related stenosis had significantly higher annual costs ($5286.56 vs $2873.62, P =. 03). The cost of CTR/TR was $8583.91 (SE, $2263.22). Over a 5‐year time horizon, CTR/TR gained $896 per QALY over serial dilations and was cost‐effective. Over a 10‐year time horizon, CTR/TR dominated dilations with a lower cost and higher QALY.ConclusionThe cost of treatment for LTS is significant. Patients with intubation‐related stenosis have significantly higher annual costs than do idiopathic patients. CTR/TR contributes significantly to cost in LTS but is cost‐effective versus endoscopic dilations for appropriately selected patients over a 5‐ and 10‐year horizon.
Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case–Control Study and a Meta-analysis
Amirian, E. Susan , Ostrom, Quinn T. , Armstrong, Georgina , Lai, Rose , Gu, Xiangjun, Jacobs, Daniel I. , Jalali, Ali , Claus, Elizabeth B. , Barnholtz‐Sloan, Jill S. , Il’yasova, Dora , Schildkraut, Joellen M. , Ali‐Osman, Francis, Sadetzki, Siegal , Jenkins, Robert B. , Bernstein, Jonine L. , Merrell, Ryan , Wrensch, Margaret , Johansen, Christoffer , Houlston, Richard S. , Shete, Sanjay , Melin, Beatrice , Bondy, Melissa L. , Houlston, Richard S , Amos, Christopher I , Barnholtz-Sloan, Jill S , Armstrong, Georgina , Lachance, Daniel Honore , Olson, Sara H. , Amos, Christopher I. , Ostrom, Quinn T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 27, 2018 | Volume: 28 | Issue: 3 | Pages: 555-562

10.1158/1055-9965.epi-18-0702 | PMID 30482874 Get It

Abstract Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR = 0.62; 95% confidence interval (CI), 0.54–0.70]. There was a significant duration-response trend (P = 1.67 × 10−17), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70–1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.
The experience of parents with children with myelomeningocele who underwent prenatal surgery
Antiel, Ryan M. , Blaine, Kallie, Fry, Jessica T. , Howell, Lori J. , Houtrow, Amy J. , Janvier, Annie , Feudtner, Chris

Mayo Clinic

Journal of Pediatric Rehabilitation Medicine | November 27, 2018 | Volume: 11 | Issue: 4 | Pages: 217-225

10.3233/prm-170483 | PMID 30507587 Get It

Interaction of hypoxia and vascular occlusion on cardiorespiratory responses during exercise
Keller‐Ross, Manda L. , Sarkinen, Andrielle L., Chantigian, Daniel P. , Johnson, Bruce D., Olson, Thomas P. , Keller-Ross, Manda , Cross, Troy J.

Mayo Clinic

Translational Sports Medicine | November 27, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/tsm2.60 Get It

Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1
Nicolas, Clara T., Allen, Kari L. , Mao, Shennen A. , Elgilani, Faysal, Glorioso, Jaime , Amiot, Bruce , VanLith, Caitlin J. , Guthman, Rebekah M., Du, Zeji , Chen, Harvey , Kaiser, Robert A. , Nyberg, Scott L. , Lillegard, Joseph B. , Hickey, Raymond D, Allen, Kari, Mao, Shennen, VanLith, Caitlin, Guthman, Rebekah, Mao, Shennen A , Hickey, Raymond , Harding, Cary O.

Mayo Clinic

Cell Transplantation | November 27, 2018 | Volume: 28 | Issue: 1 | Pages: 79-88

10.1177/0963689718814188 | PMID 30477316 Get It

Orthotopic liver transplantation remains the only curative therapy for inborn errors of metabolism. Given the tremendous success for primary immunodeficiencies using ex-vivo gene therapy with lentiviral vectors, there is great interest in developing similar curative therapies for metabolic liver diseases. We have previously generated a pig model of hereditary tyrosinemia type 1 (HT1), an autosomal recessive disorder caused by deficiency of fumarylacetoacetate hydrolase (FAH). Using this model, we have demonstrated curative ex-vivo gene and cell therapy using a lentiviral vector to express FAH in autologous hepatocytes. To further evaluate the long-term clinical outcomes of this therapeutic approach, we continued to monitor one of these pigs over the course of three years. The animal continued to thrive off the protective drug NTBC, gaining weight appropriately, and maintaining sexual fecundity for the course of his life. The animal was euthanized 31 months after transplantation to perform a thorough biochemical and histological analysis. Biochemically, liver enzymes and alpha-fetoprotein levels remained normal and abhorrent metabolites specific to HT1 remained corrected. Liver histology showed no evidence of tumorigenicity and Masson’s trichrome staining revealed minimal fibrosis and no evidence of cirrhosis. FAH-immunohistochemistry revealed complete repopulation of the liver by transplanted FAH-positive cells. A complete histopathological report on other organs, including kidney, revealed no abnormalities. This study is the first to demonstrate long-term safety and efficacy of hepatocyte-directed gene therapy in a large animal model. We conclude that hepatocyte-directed ex-vivo gene therapy is a rational choice for further exploration as an alternative therapeutic approach to whole organ transplantation for metabolic liver disease, including HT1.
Biparental Inheritance of Mitochondrial DNA in Humans
Luo, Shiyu , Valencia, C. Alexander , Zhang, Jinglan , Lee, Ni‐Chung , Slone, Jesse , Gui, Baoheng , Wang, Xinjian , Li, Zhuo , Dell, Sarah, Brown, Jenice, Chen, Stella Maris, Hwu, Wuh‐Liang , Fan, Pi‐Chuan , Wong, Lee-Jun, Huang, Taosheng , Li, Zhuo , Chien, Yin-Hsiu , Atwal, Paldeep S

Mayo Clinic

Proceedings of the National Academy of Sciences | November 26, 2018 | Volume: 115 | Issue: 51 | Pages: 13039-13044

10.1073/pnas.1810946115 | PMID 30478036 Get It

Significance The energy-producing organelle mitochondrion contains its own compact genome, which is separate from the nuclear genome. In nearly all mammals, this mitochondrial genome is inherited exclusively from the mother, and transmission of paternal mitochondria or mitochondrial DNA (mtDNA) has not been convincingly demonstrated in humans. In this paper, we have uncovered multiple instances of biparental inheritance of mtDNA spanning three unrelated multiple generation families, a result confirmed by independent sequencing across multiple unrelated laboratories with different methodologies. Surprisingly, this pattern of inheritance appears to be determined in an autosomal dominantlike manner. This paper profoundly alters a widespread belief about mitochondrial inheritance and potentially opens a novel field in mitochondrial medicine.
Clinical Progression in Four Cases of Primary Progressive Apraxia of Speech
Boland, Sarah, Whitwell, Jennifer L. , Josephs, Keith A. , Strand, Edythe A. , Boland, Sarah M, Utianski, Rene L. , Duffy, Joseph R. , Clark, Heather M. , Machulda, Mary M. , Whitwell, Jennifer L.

Mayo Clinic

American Journal of Speech-Language Pathology | November 26, 2018 | Volume: 27 | Issue: 4 | Pages: 1303-1318

10.1044/2018_ajslp-17-0227 | PMID 30458509 Get It

Purpose This case series details the clinical progression of patients with primary progressive apraxia of speech (PPAOS) to illustrate, using several methods and supplemental material examples, the changes that occur in speech and language functioning in this patient population. Method Four patients who presented with PPAOS were followed between 5 and 6 years. Two patients had predominant articulatory abnormalities (termed phonetic PPAOS ), 1 had predominant prosodic abnormalities (prosodic PPAOS), and 1 had relatively equal articulatory and prosodic abnormalities (mixed PPAOS). Detailed speech (including acoustics), language, neurologic, and neuropsychological data were collected. Results At initial exam, the patients ranged from 60 to 77 years old, with presenting disease duration of 1.5–10 years. Although all patients presented with an isolated apraxia of speech, all developed varying degrees of aphasia and dysarthria. Patients with phonetic PPAOS developed relatively more severe aphasia than the other 2 patients. All patients eventually had severe functional communication limitations and required alternative or augmentative means of communication, although at varying times postonset of their initial speech problem. Two patients developed dysphagia, 3 showed mild–moderate Parkinsonism, and 2 developed depression. For all patients, simple temporal acoustic measurements documented slowed speech rate over time. Conclusions This case series demonstrates that patients who initially present with PPAOS may develop aphasia and dysarthria, cognitive and behavioral changes, and other neurologic signs. Whether these changes can be predicted by the perceptual characteristics of the apraxia of speech is yet to be determined. The detailed longitudinal profiles provide valuable clinical insight into the progression of disease in people with PPAOS. Supplemental Material https://doi.org/10.23641/asha.7051616
Reasons for Declining Consent in a Population-Based Cohort Study Conducted in a Rural South American Community
Brutto, Óscar H. Del , Castillo, Pablo R. , Sedler, Mark J. , Brutto, Víctor J. Del , Zambrano, Mauricio, Mera, Robertino M. , Del Brutto, Oscar H , Castillo, Pablo R , Wright, Clinton B. , Rundek, Tatjana , Del Brutto, Victor J

Mayo Clinic

Journal of Environmental and Public Health | November 26, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-7

10.1155/2018/8267948 | PMID 30598669 Get It

There is limited information on participants’ adherence and reasons for declining consent in observational cohort studies conducted in remote rural communities. We aimed at sharing lessons learned during the Atahualpa Project, a population-based cohort study conducted in a rural Ecuadorian village. Atahualpa residents aged ≥40 years identified during door-to-door surveys who signed a consent form were enrolled. Annual surveys were conducted to assess the number of participants who moved out of the village, as well as those who died, declined consent, and newly entered the study. Reasons for declining consent were tabulated. Abstracted data included age, sex, education, disability, time between enrollment and declining consent, and reasons for withdrawal. We also counted participants who, despite expressing their willingness to continue in the study, refused specific procedures. After five years of follow-up, 54 (6.3%) of 863 enrolled individuals declined consent. Increasing age and disability had no impact on declining consent. In contrast, refusal was higher among relatives or neighbors of a given participant declining consent. Most people who declined consent did so after one or two years of enrollment. Less than 20% of enrolled individuals refused certain procedures. “Fear of the needle” was the most frequent reason for refusing blood tests, and common reasons for declining complimentary exams were lack of interest and time constraints. Cohort retention in the Atahualpa Project is high. Main reasons for this adherence include adequate selection of the village, detailed planning of procedures, assurance of sponsorship, and field personnel who continuously engage with study participants. This trial is registered with NCT01627600.
Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Chung, Arlene E. , Shoenbill, Kimberly A. , Dueck, Amylou C. , Bruner, Deborah Watkins , Minasian, Lori M. , Germain, Diane St. , O’Mara, Ann M., Baumgartner, Paul , Rogak, Lauren J. , Griffin, Ashley C , Basch, Ethan , Dueck, A. C. , Bruner, Deborah , Mitchell, Sandra A , Schrag, Deborah , Abernethy, Amy P. , Basch, Ethan

Mayo Clinic

Journal of the American Medical Informatics Association | November 26, 2018 | Volume: 26 | Issue: 4 | Pages: 276-285

10.1093/jamia/ocy169 | PMID 30840079 Get It

Abstract Objective The study sought to describe patient-entered supplemental information on symptomatic adverse events (AEs) in cancer clinical research reported via a National Cancer Institute software system and examine the feasibility of mapping these entries to established terminologies. Materials and Methods Patients in 3 multicenter trials electronically completed surveys during cancer treatment. Each survey included a prespecified subset of items from the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Upon completion of the survey items, patients could add supplemental symptomatic AE information in a free text box. As patients typed into the box, structured dropdown terms could be selected from the PRO-CTCAE item library or Medical Dictionary for Regulatory Activities (MedDRA), or patients could type unstructured free text for submission. Results Data were pooled from 1760 participants (48% women; 78% White) who completed 8892 surveys, of which 2387 (26.8%) included supplemental symptomatic AE information. Overall, 1024 (58%) patients entered supplemental information at least once, with an average of 2.3 per patient per study. This encompassed 1474 of 8892 (16.6%) dropdowns and 913 of 8892 (10.3%) unstructured free text entries. One-third of the unstructured free text entries (32%) could be mapped post hoc to a PRO-CTCAE term and 68% to a MedDRA term. Discussion Participants frequently added supplemental information beyond study-specific survey items. Almost half selected a structured dropdown term, although many opted to submit unstructured free text entries. Most free text entries could be mapped post hoc to PRO-CTCAE or MedDRA terms, suggesting opportunities to enhance the system to perform real-time mapping for AE reporting. Conclusions Patient reporting of symptomatic AEs using a text box functionality with mapping to existing terminologies is both feasible and informative.